
Loading, please wait...

Loading, please wait...

This systematic review and network meta-analysis compared five FDA-approved atypical antipsychotics used adjunctively in major depressive disorder. Twenty-two short-term studies involving 10,962 participants were analyzed: aripiprazole (n=1,297), brexpiprazole (n=1,973), cariprazine (n=1,894), lumateperone (n=483), quetiapine XR (n=719), and placebo (n=4,596). For ≥50% reduction in MADRS scores, lumateperone showed RR 1.72 (95% CrI 1.40–2.15), followed by aripiprazole 1.53 (1.32–1.77), brexpiprazole 1.38 (1.18–1.65), cariprazine 1.20 (1.07–1.36), and quetiapine XR 1.15 (0.96–1.35). For acceptability, assessed by all-cause discontinuation, aripiprazole had RR 1.16 (0.89–1.50), while lumateperone had RR 2.30 (1.45–3.84). The analysis also examined symptomatic remission and clinically significant weight gain. The authors emphasize differences across agents in efficacy, acceptability, and tolerability, while noting limited evidence for maintenance efficacy.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This systematic review and network meta-analysis compared five FDA-approved atypical antipsychotics used adjunctively in major depressive disorder. Twenty-two short-term studies involving 10,962 participants were analyzed: aripiprazole (n=1,297), brexpiprazole (n=1,973), cariprazine (n=1,894), lumateperone (n=483), quetiapine XR (n=719), and placebo (n=4,596). For ≥50% reduction in MADRS scores, lumateperone showed RR 1.72 (95% CrI 1.40–2.15), followed by aripiprazole 1.53 (1.32–1.77), brexpiprazole 1.38 (1.18–1.65), cariprazine 1.20 (1.07–1.36), and quetiapine XR 1.15 (0.96–1.35). For acceptability, assessed by all-cause discontinuation, aripiprazole had RR 1.16 (0.89–1.50), while lumateperone had RR 2.30 (1.45–3.84). The analysis also examined symptomatic remission and clinically significant weight gain. The authors emphasize differences across agents in efficacy, acceptability, and tolerability, while noting limited evidence for maintenance efficacy.
2 months ago

A multicenter study validates a machine learning-guided recalibrated SOFA score, demonstrating significantly improved ICU mortality discrimination while preserving the simple, additive, point-based structure critical for bedside decision-making.
Yesterday

A landmark study reveals that lipid-rich malignant ascites alters the T-cell metabolic transcriptome, causing cholesterol efflux and impaired fatty acid oxidation. This suppresses TCR signalling and blocks BiTE immunotherapy, while lipid depletion restores antitumour cytotoxicity in ovarian cancer.
Yesterday

Researchers have engineered novel light-on photoswitchable adrenoceptor agonists targeting β1-receptors. By remaining inactive until illuminated, these precision molecules offer reversible optical control, tailored relaxation kinetics, and distinct efficacy profiles, paving the way for targeted cardiovascular therapies.
2 days back

A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 weeks back

This review examines the pharmacogenomics of antidiabetic agents, highlighting how genetic variations in SLC2A2, SLC47A1, CYP2C9, ABCC8, and GLP1R influence drug transport, therapeutic efficacy, and hypoglycemia risk to enable tailored precision medicine in type 2 diabetes.
Yesterday